WA-REVALVE-SOLUTIONS
ReValve Solutions, Inc., an innovator in the field of transcatheter structural heart replacement and repair, announced today it has successfully completed the first human use of its transcatheter, Palmetto System for mitral valve replacement. The patient was successfully treated who suffered from severe mitral valve regurgitation and heart failure. The transfemoral-transseptal procedure was performed at the Italian Hospital in Asuncion, Paraguay by Dr. Charles Davidson, (Medical Director, Bluhm Cardiovascular Institute) and Dr. Edris Aman, (Assistant Clinical Professor of Cardiovascular Medicine at the University of California, Davis Medicine Center specialized in Multimodality Imaging).
"The complexity of mitral valve pathology creates challenges for transcatheter therapies to treat effectively. The first in human experience with this innovative technology shows promise for patients with advanced mitral valve regurgitation,” said Charles Davidson, MD.
"The features of the Palmetto System allow for transseptal mitral valve replacement in native mitral regurgitation. This case highlights the potential for this technology, which is another step forward for transseptal mitral valve replacement,” said Edris Aman, MD.
“The case is a major step forward in Re-Imaging the treatment of structural heart disease. Our unique portfolio of technologies is based on our understanding of the evolution of disease and the need to provide for ongoing management of valvular heart disease. I am extremely proud of our team’s focus and dedication,” said Julie Logan Sands, CEO and Founder of ReValve Solutions
The Palmetto System is a complete mitral valve replacement. It is delivered via transfemoral-transeptal procedure. The system is design to avoid any disturbance to the left-ventricular outflow tract and if needed will allow for future valve replacement without compromising the orifice area. Preserving options for the physician and patient is an essential part of the solution to structure heart treatment.
About ReValve Solutions, Inc.
ReValve Solutions, Inc. (www.revalvesolutions.com ) is based in, Washington with the mission of delivering innovative solutions to structure heart disease through catheter-based procedures. Solutions that are tailored to the needs of the patient. For more information visit www.ReValveSolutions.com
Related Links http://www.revalvesolutions.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005797/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelera Announces Europa AIPU, Setting New Industry Benchmark for AI Accelerator Performance, Power Efficiency and Affordability21.10.2025 14:00:00 CEST | Press release
Delivers 629 TOPs processing power for multi-modal AI applications from the edge to the data center Axelera AI, the leading provider of purpose-built AI hardware acceleration technology, today announced Europa™, an AI processor unit (AIPU) that sets a new performance/price standard for multi-user generative AI and computer vision applications. Europa’s combination of processing power, energy and thermal efficiency, compact packaging, and multiple form factor options make it ideal for compute-intensive, multi-modal AI inference applications from the edge to enterprise servers. Designed to be cost effective and accessible, Europa enables any organization to unlock the power of cutting-edge AI applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021493990/en/ Europa™ AIPU Next Gen Architecture for Real World AI Processing Power The Europa AIPU features eight second-generation AI cores, each incorporating Axelera’s ad
Enedym Inc. Secures Investment from Honda Motor Co., Ltd.21.10.2025 14:00:00 CEST | Press release
Enedym’s next generation switched reluctance motor (SRM) drive technology requires no permanent magnets or rare earth metals Enedym Inc. (“Enedym”), a technology company thatdevelops next generation switched reluctance motors (SRMs), electric powertrains, and powertrain controls, announced today an investment from Honda Motor Co., Ltd. (“Honda”). Honda invests in innovative startups through its global open innovation program, Honda Xcelerator Ventures. The new investment will be used to accelerate Enedym’s patented motor technology development and ramp up its operations. Enedym is headquartered at the McMaster Innovation Park in Hamilton, Ontario, Canada. Enedym has ownership of over 70 patents and pending patent applications and related inventions developed by the Canada Excellence Research Chair Laureate Dr. Ali Emadi and his research group at the McMaster Automotive Resource Centre (MARC), McMaster University. The Company is focused on the development of electric motors completely f
ExaGrid Named Finalist for the MSP Channel Awards 202521.10.2025 14:00:00 CEST | Press release
ExaGrid Nominated in 7 Categories for Inaugural Industry Awards ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it has been nominated in six categories for the 1st annual MSP Channel Awards, which celebrates innovation across the IT Channel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021571422/en/ The new MSP Channel Awards build on the legacy of the former SDC Awards to better reflect today's fast-moving IT landscape. As managed services reshape how technology is delivered – from digital transformation and cybersecurity to cloud, data, and automation – these awards recognize the companies, partnerships, and individuals making a real impact across the channel. Voting to determine the winner in each category i
Carevance platform expands access to GE HealthCare’s clinical excellence with advanced patient monitoring and new perioperative hypotension management capability21.10.2025 14:00:00 CEST | Press release
Built on GE HealthCare’s 50+ years of clinical excellence in patient monitoring, Carevance is an advanced, reliable monitoring solution that leverages proprietary algorithms and proven technologies to help hospitals and clinicians deliver consistent, high-quality care. Designed for today’s clinical realities, Carevance helps support clinicians across acute care areas through an enhanced intra-hospital transport workflow and real-time patient data. As part of its capabilities, Carevance introduces the new Cardiac Output Insights feature available directly on the device to support caregivers in managing hemodynamic instability for perioperative care and help enable timely clinical interventions. Hemodynamic instability or hypotension is a common concern for care teams to manage during and after surgery, and can be associated with longer hospital stays and serious postoperative complications, such as organ failure and mortality.i,ii GE HealthCare (Nasdaq: GEHC) today announced it has rece
Wilmington PharmaTech Continues Expansion with Significant Investment from Curewell Capital21.10.2025 14:00:00 CEST | Press release
Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development, and manufacturing organization (CRDMO) focused on custom small molecule API development and manufacturing, today announced a majority investment by Curewell Capital (“Curewell”), a Los Angeles-based private equity firm focused on building industry-leading healthcare companies. Hui-Yin “Harry” Li, Ph.D., Founder and CEO of WPT, will retain a significant ownership stake and will continue to lead the business alongside the management team. The partnership with Curewell will provide significant growth capital to expand WPT’s manufacturing capacity and further scale its end-to-end capabilities in producing a full range of small molecule API in the U.S. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021135557/en/ Founded in 2003, WPT has built extensive expertise across hundreds of novel drug substance programs, spanning complex synthesis, med
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom